Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBT (2016 - 2026)

Amphastar Pharmaceuticals has reported EBT over the past 13 years, most recently at $37.2 million for Q4 2025.

  • For Q4 2025, EBT fell 24.57% year-over-year to $37.2 million; the TTM value through Dec 2025 reached $129.0 million, down 33.93%, while the annual FY2025 figure was $129.0 million, 33.93% down from the prior year.
  • EBT for Q4 2025 was $37.2 million at Amphastar Pharmaceuticals, up from $21.5 million in the prior quarter.
  • Over five years, EBT peaked at $63.6 million in Q3 2023 and troughed at -$140.6 million in Q4 2023.
  • A 5-year average of $19.3 million and a median of $31.8 million in 2023 define the central range for EBT.
  • Biggest five-year swings in EBT: surged 1045.28% in 2021 and later crashed 416.41% in 2022.
  • Year by year, EBT stood at $27.2 million in 2021, then crashed by 416.41% to -$85.9 million in 2022, then tumbled by 63.57% to -$140.6 million in 2023, then skyrocketed by 135.12% to $49.4 million in 2024, then dropped by 24.57% to $37.2 million in 2025.
  • Business Quant data shows EBT for AMPH at $37.2 million in Q4 2025, $21.5 million in Q3 2025, and $39.3 million in Q2 2025.